We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

EIKEN CHEMICAL

EIKEN CHEMICAL CO., LTD. provides clinical diagnostic aids, including biochemical, immunological, serological, dry ch... read more Featured Products: More products

Download Mobile App




Stool DNA Test Helps Detect Precancerous Lesions

By LabMedica International staff writers
Posted on 27 Dec 2019
Colorectal cancer (CRC) is the third most common cancer and is one of the leading causes of cancer-related mortality. More...
Although CRC incidence is increasing, a decrease in mortality has been observed due to the implementation of CRC screening and improved therapies.

CRC screening not only leads to a reduction in morbidity and mortality, but also to a lower CRC incidence when neoplastic lesions can be detected and removed at a premalignant stage. Therefore, CRC screening is considered cost-effective or even cost saving. Currently, colonoscopy is used for opportunistic screening programs in the USA, whereas in Europe, fecal immunochemical test (FIT) is the first choice for CRC screening in invitation-based screening programs.

Pathology scientists at the Netherlands Cancer Institute (Amsterdam, The Netherlands) and their colleagues prospectively collected 1,047 whole stool samples. Histology assessment was carried out and lesions were categorized as non-neoplastic, serrated polyp, adenoma, or carcinoma. Fecal immunochemical tests (FIT, OC-Sensor, Eiken Chemical, Tokyo, Japan) were performed by the screening participants before their preparation for screening colonoscopy.

A multitarget stool DNA test (MT-sDNA) was applied to all stool samples for DNA marker analysis that were collected and processed according to a uniform standard operational procedure and analyzed at Exact Sciences Laboratory (Madison, WI, USA). The team evaluated the efficacy of the MT-sDNA test that evaluates for KRAS mutations and NDRG4 and BMP3 promoter methylation in addition to testing for hemoglobin.

The team determined that the MT-sDNA test was more sensitive than FIT for the detection of precancerous lesions (46% versus 27%). While MT-sDNA detected 24 of 119 advanced lesions that were not detected by FIT, FIT detected just one precancerous lesion that was missed by MT-sDNA. The specificity for the MT-sDNA and FIT among individuals with non-advanced or negative findings was 89% and 93%, respectively. The two tests had similar sensitivity for detecting individuals with high-risk advanced adenomas from individuals with low-risk adenomas. A positive MT-sDNA test was associated with multiple lesions, larger lesions, and lesions with tubulovillous architecture.

The authors concluded that the MT-sDNA test combining DNA methylation and mutation markers with hemoglobin has a significantly increased sensitivity for advanced precancerous lesions than FIT alone at equal specificity, indicating its potential for application in population screening for CRC. Based on extensive cost-effectiveness evaluation, many organized screening programs use FIT as a triage test to select individuals for colonoscopy. Although detection of blood in stool has shown to be successful in reducing mortality from CRC, sensitivity can still be improved. The study was published in the December, 2019 issue of The American Journal of Gastroenterology.

Related Links:
Netherlands Cancer Institute
Eiken Chemical
Exact Sciences Laboratory



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.